Besides, the GLP-1R/GGCR dual agonist, Cotadutide, was shown to relieve steatosis, inflammation and fibrosis in both Ob/Ob NASH mice model and C57BI/6J NASH mice model (131)
The Cox proportional cause-specific hazard models (table 4) revealed no increased risk of pregnancy loss in either the comparison between the GLP1-RA group and the diabetes reference group or the overweight/obese reference group
GIP also supported de novo lipogenesis from glucose as well as lipolysis (the mobilisation of FFA in the fasting state)
Lancet 404 , 773786 (2024)
More serious but less common risks can include: Gallbladder disease Pancreatitis Worsening of diabetic retinopathy in patients with diabetes Thyroid C-cell tumors observed in animal studies Certain conditions, medications, or risk factors may influence whether a healthcare provider thinks GLP-1s are appropriate for you, so women should review their full medical history with a qualified provider before starting therapy